The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
09-Sep-24
Undisclosed
Target:
Pixelligent Technologies
Acquiror:
Henkel Corporation
Advised Pixelligent Technologies, a developer and manufacturer of nanocrystal material used in consumer electronic devices, on a significant strategic investment from Henkel Corporation, a publicly traded (FWB: HEN) German multinational chemical and consumer goods company
27-Sep-23
Undisclosed
Target:
Slayback Pharma LLC
Acquiror:
Azurity Pharmaceuticals
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
19-Sep-23
$60 million
Target:
Williams Industrial Services Group
Acquiror:
EnergySolutions
Advised Williams Industrial Services Group, (NYSE: WLMS), a maintenance & construction services provider to the commercial nuclear power and heavy industry markets, on its Section 363 sale to EnergySolutions, a global provider of nuclear, energy and industrial services
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
03-Nov-22
Undisclosed
Target:
Pixelligent Technologies
Acquiror:
MVolution Partners
Advised Pixelligent Technologies, a leading manufacturer of nanocrystal material used in consumer electronic devices, on its growth capital raise
19-Aug-22
$2.2 billion
Target:
GI Alliance
Acquiror:
Apollo Hybrid Value Fund
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
01-Jun-22
$537 million
Target:
NAC 33 & NAC 34, subsidiaries of Nordic Aviation Capital
Acquiror:
Azorra Aviation
Advised Azorra Aviation, a leading commercial aircraft lessor backed by Oaktree Capital Management, on the chapter 11 restructuring and related investment in NAC 33 & 34, two exiting subsidiaries of Nordic Aviation Capital
29-Mar-22
$2.6 billion
Target:
Wesco Aircraft Holdings, Inc. dba Incora
Acquiror:
N/A
Advised Carlyle Global Credit Investment Management LLC, the majority holder of the Incora’s unsecured notes, with respect to a comprehensive recapitalization transaction
17-Dec-21
N.A.
Target:
MRO Holdings, Inc. (Panama)
Acquiror:
N.A.
Advised MRO Holdings, a leading airframe maintenance, repair and overhaul (“MRO”) services provider in the Americas, on its term loan financing
29-Sep-21
Pending
$250 million
Target:
Universal Fiber Systems
Acquiror:
N/A
Advised Universal Fiber Systems, a leading supplier of solution-dyed fibers, on its $250mm Unitranche Term Loan financing
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
09-Feb-21
Undisclosed
Target:
US Acute Care Solutions
Acquiror:
Apollo Hybrid Value Fund
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
01-Oct-20
$1.05 billion
Target:
Akorn, Inc.
Acquiror:
First Lien Term Loan Lenders
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
29-Sep-20
$200 million
Target:
Travel & Transport
Acquiror:
Corporate Travel Management
Advising Corporate Travel Management on its acquisition of US-based travel management company Travel & Transport and the associated A$375mm equity raise
30-Apr-20
$1.9 billion
Target:
American Commercial Lines
Acquiror:
N/A
Advised American Commercial Lines, a leading provider of maritime transportation services, on its pre-packaged in-court recapitalization
03-Feb-20
$650 million
Target:
Clover Wireless
Acquiror:
First Lien Term Loan B Lenders
Advised Ad Hoc Group of First Lien Term Loan B Lenders on the restructuring of 4L Holdings Corporation
08-May-19
$770 million
Target:
Neovia Logistics
Advised Oaktree Capital Management on the comprehensive recapitalization of Neovia
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
28-Mar-18
$NA
Target:
Willbros Group, Inc.
Acquiror:
Primoris Services Corporation
Advised Willbros Group, Inc., a specialty energy infrastructure contractor serving the power and oil & gas industries, on its sale to Primoris Services Corporation
23-Feb-17
$1.1 billion
Target:
Natural Resource Partners L.P.
Advised Natural Resource Partners L.P., a publicly-traded master limited partnership that owns, manages and leases mineral properties in the United States, on a series of recapitalization transactions including the extension of NRP’s near-term debt maturities and the issuance of $250mm of new preferred equity capital to funds managed by Blackstone Tactical Opportunities and from several affiliates of GoldenTree Asset Management L.P.
25-Jan-17
$325 million
Target:
Ad Hoc Group of Senior Secured Noteholders
Advised the Ad Hoc Group of Senior Secured Noteholders in connection with the restructuring of Goodman Networks.
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
08-Jul-16
$555 million
Target:
New Enterprise Stone & Lime Co., Inc.
Advised New Enterprise Stone & Lime Co., Inc. on $555 million of secured financings, including a new $450 million senior secured term loan and substantial amendments to its existing $105 million ABL revolver
17-Dec-15
$130 million
Target:
Airopack Technology Group AG
Acquiror:
Apollo Global Management, LLC
Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV
23-Oct-14
$NA
Target:
Boart Longyear Ltd.
Advised the Board of Directors of Boart Longyear, the world’s leading supplier of drilling services and equipment for mining and drilling companies, on its strategic review process and subsequent comprehensive recapitalization transactions with certain affiliates of Centerbridge Partners, L.P.